+ 33 1 46 99 68 20

DELBERT Pharma news

Carbon Footprint of DELBERT Pharma

As a mission driven company, DELBERT Pharma has embedded in its mission the commitment to take concrete action in favor of accessible healthcare, while contributing to a more sustainable future. In line with this commitment, we conducted our first Carbon Footprint...

read more

Delbert Pharma awarded Mission-driven company status

Paris, 09/27/2023 Delbert Pharma, a major player in the safeguarding and relocation of essential medicines, is proud to announce that it has officially been awarded Mission-driven company status in September 2023. This recognition, the fruit of intense collaborative...

read more

New investment in Laboratoires Delbert

Vivalto Partners announces a significant investment in Laboratoires Delbert to support the company's development in the field of essential and orphan drugs. The historical investors - Sagard NewGen, Socadif Capital Investissement, IDIA Capital Investissement and MACSF...

read more

REQUEST MEDICAL INFORMATION - REPORT AN ADVERSE EVENT

To request medical information on DELBERT Pharma products or report an adverse event,

please write to pharmacovigilance@delbert.fr or contact us on + 33 1 46 99 68 20